Nocardiosis: 7‐year experience at an Australian tertiary hospital
Authors:
- 8 August 2018
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 49 (3) , 373-379
Abstract
Background: Nocardiosis has historically been reported in immunocompromised patients, but Australian epidemiological and antimicrobial susceptibility data are limited.Aim: To describe the epidemiology, diagnosis and initial treatment of nocardiosis in an Australian tertiary hospital over 7 years.Methods: In this retrospective study, all positive cultures for Nocardia species from any site isolated at the Alfred Hospital, Melbourne, between 1 January 2010 and 31 December 2016 were identified, and corresponding laboratory data and medical records reviewed.Results: Sixty‐eight non‐duplicate isolates were identified from 67 patients. Common predisposing factors were chronic lung disease (38/67; 57%), organ, particularly lung, transplantation (13/67; 19%) and solid organ malignancy (6/67; 9%); 12% (8/67) of patients had no identifiable systemic risk factors. Seventy‐nine percent (53/67) of patients had pulmonary nocardiosis only. Nocardia nova was the most commonly isolated species (20/68; 29%). In 48% (32/67) of patients, Nocardia species were isolated only on specific mycobacterial media. All tested species were susceptible to sulfamethoxazole‐trimethoprim and amikacin, with the majority (58/63; 92%) susceptible to imipenem. All‐cause mortality rates at 6 and 12 months where data were available were 15% (10/66 patients) and 22% (14/64 patients) respectively.Conclusion: In the largest Australian series in 25 years, nocardiosis predominantly affected patients with chronic lung disease or impaired cell‐mediated immunity. A significant proportion of organisms from pulmonary sites were isolated on mycobacterial culture media only, suggesting that its use may improve yield. Isolates remain highly susceptible to sulfamethoxazole‐trimethoprim, amikacin and imipenem, while other agents should be used only after confirmation of in vitro susceptibility.Keywords
This publication has 27 references indexed in Scilit:
- Nocardia Infections in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Nocardiosis: Updates and Clinical OverviewMayo Clinic Proceedings, 2012
- Sulfonamide Resistance in Isolates of Nocardia spp. from a U.S. Multicenter SurveyJournal of Clinical Microbiology, 2012
- Multicenter Study in Taiwan of the In Vitro Activities of Nemonoxacin, Tigecycline, Doripenem, and Other Antimicrobial Agents against Clinical Isolates of Various Nocardia SpeciesAntimicrobial Agents and Chemotherapy, 2011
- Clinical and microbiological characteristics of infections caused by various Nocardia species in Taiwan: a multicenter study from 1998 to 2010European Journal of Clinical Microbiology & Infectious Diseases, 2011
- Antimicrobial‐ResistantNocardiaIsolates, United States, 1995–2004Clinical Infectious Diseases, 2010
- Antimicrobial Susceptibility Testing and Profiling of Nocardia Species and Other Aerobic Actinomycetes from South Africa: Comparative Evaluation of Broth Microdilution versus the EtestJournal of Clinical Microbiology, 2010
- Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by EtestClinical Microbiology and Infection, 2006
- NocardiaInfection in Heart‐Lung Transplant Recipients at Alfred Hospital, Melbourne, Australia, 1989–1998Clinical Infectious Diseases, 2000
- Comparative evaluation of the E test for susceptibility testing of Nocardia speciesDiagnostic Microbiology and Infectious Disease, 1994